GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Ariad Pharmaceuticals, Inc. (ARIA) [hlAlert]

Rating:
Outperform
ARIA
down 22.78 %

Ariad Pharmaceuticals, Inc. (ARIA) upgraded to Outperform with price target $14 by BMO Capital Markets

Posted on: Friday,  Jan 24, 2014  3:25 PM ET by BMO Capital Markets

BMO Capital Markets rated Outperform Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) on 01/24/2014, when the stock price was $9.04.
Since then, Ariad Pharmaceuticals, Inc. has lost 22.79% as of 01/19/2016's recent price of $6.98.
If you would have followed this BMO Capital Markets's recommendation on ARIA, you would have lost 22.78% of your investment in 725 days.

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.

The U.S. Equity Research team comprises over 25 analysts located in New York, Atlanta, Boston, Denver, Houston and Los Angeles. We cover more than 375 stocks and also provide equity strategy, quantitative analysis and portfolio management services to our clients. Our goal is to identify the best sectors to invest in, and the best stocks within those sectors, in order to help our clients maximize their portfolio returns. Our award-winning analysts provide research that is informative, perceptive and actionable.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/24/2014 3:25 PM Buy
None
9.04 14.00
as of 10/17/2014
1 Week up  8.36 %
1 Month down  -7.95 %
3 Months up  8.58 %
1 YTD down  -39.82 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/20/2013 1:25 PM Hold
None
6.83 8.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy